There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Actinium Pharmaceuticals (NYSE: ATNM) and Vital Therapies (NASDAQ: VTL) with bullish sentiments.

Actinium Pharmaceuticals (NYSE: ATNM)

In a report released today, George Zavoico from B.Riley FBR assigned a Buy rating to Actinium Pharmaceuticals (NYSE: ATNM), with a price target of $2.75. The company’s shares opened today at $0.72, close to its 52-week low of $0.54.

Zavoico noted:

“Summary and Recommendation We are initiating coverage of Actinium Pharmaceuticals, Inc. (NASDAQ: ATNM) with a 12- month price target of $2.75 per share based on its novel approach to treating certain blood cancers. Actinium Pharma’s clinical development plan targets unmet clinical needs in which no effective therapies are approved. We think the company’s differentiated approach will establish antibody-radioisotope conjugates (ARCs) in indications with no other approved therapies, enhancing the potential for greater market penetration. We think this is underappreciated by investors, which makes Actinium Pharma a compelling investment opportunity. Actinium Pharma’s preliminary Phase II results showed a 56% objective response rate and a 22% complete response rate with Actimab-A in previously untreated elderly patients with acute myeloid leukemia (AML) who were ineligible for chemotherapy.”

According to TipRanks.com, Zavoico is ranked #3953 out of 4729 analysts.

Currently, the analyst consensus on Actinium Pharmaceuticals is Strong Buy and the average price target is $4.19, representing a 481.9% upside.

In a report issued on November 30, Maxim Group also assigned a Buy rating to the stock with a $3 price target.Vital Therapies (NASDAQ: VTL)

In a report issued on December 4, Laura Chico from Raymond James assigned a Buy rating to Vital Therapies (NASDAQ: VTL). The company’s shares opened today at $4.85.

Chico said:

“Remain Outperform rated on VTL shares. With the company focused on a potential transition from a development-stage biotech to a commercial organization, and the recent appointment of Chairman Faheem Hasnain, we think the addition of incoming CEO Russell Cox will be well received by investors given his operational and commercialization experience. The company continues to execute on its VTL-308 study with enrollment now >80%, and potential top-line data on track for ~3Q18. Risk/reward may not be as extreme as it was earlier in 2017; however, we think the combination of continued execution and a nearing pivotal readout could make this name of interest to risk-tolerant smid-cap biotech investors.”

Vital Therapies has an analyst consensus of Hold.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.